share_log

Avalo Therapeutics | D: Filing D

Avalo Therapeutics | D: Filing D

Avalo Therapeutics | D：发行公告
SEC announcement ·  04/09 17:02
Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc. has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity and securities offering related to a business combination transaction. The offering, which began on March 27, 2024, has already seen $130,601,986 sold out of a total offering amount of $199,976,986. The securities are being offered in connection with a merger involving Project Athens Merger Sub, Inc., AlmataBio, Inc., and Second Project Athens Merger Sub, LLC. Avalo Therapeutics has declined to disclose the issuer size and has claimed an exemption under Rule 506(b) of the Securities Act. The company, based in Rockville, Maryland, operates in the biotechnology industry and has listed several executive officers and directors in the filing. No sales commissions have been reported, but finder's fees of approximately $6,937,500 have been estimated. The proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters beyond their usual compensation.
Avalo Therapeutics, Inc. has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity and securities offering related to a business combination transaction. The offering, which began on March 27, 2024, has already seen $130,601,986 sold out of a total offering amount of $199,976,986. The securities are being offered in connection with a merger involving Project Athens Merger Sub, Inc., AlmataBio, Inc., and Second Project Athens Merger Sub, LLC. Avalo Therapeutics has declined to disclose the issuer size and has claimed an exemption under Rule 506(b) of the Securities Act. The company, based in Rockville, Maryland, operates in the biotechnology industry and has listed several executive officers and directors in the filing. No sales commissions have been reported, but finder's fees of approximately $6,937,500 have been estimated. The proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters beyond their usual compensation.
Avalo Therapeutics, Inc.已向美国证券交易委员会提交了D表格的证券豁免发行通知，其中指出了与企业合并交易相关的股票和证券发行的新通知。此次发行始于2024年3月27日，在总发行额为199,976,986美元中，已售出130,601,986美元。这些证券的发行与涉及雅典项目合并子公司、AlmataBio, Inc.和第二雅典项目合并子公司的合并有关。Avalo Therapeutics拒绝透露发行人规模，并根据《证券法》第506（b）条申请豁免。该公司总部位于马里兰州罗克维尔，从事生物技术行业，并在文件中列出了几位执行官和董事。尚未报告任何销售佣金，但据估计，发现者的费用约为6,937,500美元。此次发行的收益不用于向指定执行官、董事或发起人支付超出其正常薪酬的款项。
Avalo Therapeutics, Inc.已向美国证券交易委员会提交了D表格的证券豁免发行通知，其中指出了与企业合并交易相关的股票和证券发行的新通知。此次发行始于2024年3月27日，在总发行额为199,976,986美元中，已售出130,601,986美元。这些证券的发行与涉及雅典项目合并子公司、AlmataBio, Inc.和第二雅典项目合并子公司的合并有关。Avalo Therapeutics拒绝透露发行人规模，并根据《证券法》第506（b）条申请豁免。该公司总部位于马里兰州罗克维尔，从事生物技术行业，并在文件中列出了几位执行官和董事。尚未报告任何销售佣金，但据估计，发现者的费用约为6,937,500美元。此次发行的收益不用于向指定执行官、董事或发起人支付超出其正常薪酬的款项。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息